Received date: June 22, 2016; Accepted date: July 28, 2016; Published date: July 30, 2016
Citation: Khalid A, Javaid MA (2016) Fibroblast Growth Factors and their Emerging Cancer-Related Aspects. J Cancer Sci Ther 8:190-205. doi:10.4172/1948-5956.1000413
Copyright: © 2016 Khalid A, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Visit for more related articles at Journal of Cancer Science & Therapy
Fibroblast growth factors (FGF) are proteins that are involved in several biological and developmental processes. Cell proliferation, cell motility, cell survival, and angiogenesis are the fundamental mechanisms that are carried out by these growth factors. FGF ligands when to interact with their receptors-FGFRs, elicit certain signaling pathways that ultimately lead to precise regulated cellular responses. Alterations in FGF/FGFR signaling results in various types of abnormalities. The transition of normal signaling mode of FGFs/FGFRs to an unusual functional pattern causes neurological disorders, skeletal disorders, tumor progression and tumor neovascularization. Overexpression of FGFs and FGFRs has been correlated with advanced tumor forms, mainly prostate, mammary gland, bladder and renal cell carcinomas. These GFs and their receptors are among the fundamental mediators of tumor angiogenesis, others being VEGF, Ang-1, etc. Many pharmaceutical therapies have evolved in the past years to minimize the effects of FGF/FGFR and VEGF signaling, individually as well as simultaneously. Tyrosine kinase inhibitors are the most prominent compounds that have been investigated exclusively in phase I and II clinical trials. However, the applicability of developing therapeutic techniques needs a further illustration better to comprehend the complexity of the underlying mechanism and to provide patients with a better outcome
Fibroblast growth factors; Fibroblast growth factor receptors; Cancer; Tumor growth; Angiogenesis; Biological activities; Vascular endothelial growth factor; Therapeutic inhibitors; Tyrosine kinase inhibitors
ACTH: Adrenocorticotropic Hormone; Ang: Angiopoietin; BC: Breast Cancer; Bcl-2: B-cell Lymphoma 2; ECM: Extracellular Matrix; EGF: Epidermal Growth Factor; FGF: Fibroblast Growth Factor; FGFR: Fibroblast Growth Factor Receptor; GH: Growth Hormone; hESCs: Human Embryonic Stem Cells; HGF: Hepatocyte Growth Factor; HIF: Hypoxia-Induced Factor; hMSCs: Human Mesenchymal Stem Cells; HPDE: Human Pancreatic Duct Epithelial Cells; HSPG: Heparin Sulfate Proteoglycan; IFN: Interferon; Ig-like: Immunoglobulin-like; IL: Interleukin; LH: Luteinizing Hormone; mAb: Monoclonal Antibody; MAPK: Mitogen-Activated Protein Kinases; MEK: Mitogen-Activated Protein Kinase Kinase i.e. MAPKK; MMPs: Matrix Metalloproteinases; NO: Nitric Oxide; PDGF: Platelet-Derived Growth Factor; PDGFR: Platelet-Derived Growth Factor Receptor; PGE2: Prostaglandin E2; PKC: Protein Kinase C; RTK: Receptor Tyrosine Kinase; TACC1: Transforming, Acidic Coiled-Coil Containing Protein 1; TGF: Transforming Growth Factor; Upa: Urokinase Plasminogen Activator; VEGF: Vascular Endothelial Growth Factor; VEGFR: Vascular Endothelial Growth Factor Receptor; XIAP: X-Linked Inhibitor of Apoptosis Protein.
For years, it was known that the brain and the pituitary glands enclosed some mitogenic agents . In 1973, an entity dissimilar from pituitary hormones was isolated from the bovine pituitary 3T3 fibroblasts. The identified substance was fibroblast growth factor that induced the growth of 3T3 cells . Two different forms of proteins were involved in the growth of 3T3 cells. The first one was aFGF (acidic Fibroblast Growth Factor) and the second one was bFGF (basic fibroblast growth factor). aFGF had a 5.6 isoelectric point (pI) (acidic); bFGF had >9 pI (basic). bFGF and aFGF share 55% homology within their sequences. Fibroblast growth factor-1 and Fibroblast growth factor-2 were previously known as aFGF and bFGF, respectively . With the advancing technology and usage of emerging capacities, up to 22 members of the fibroblast growth factor family have been classified in humans (Table 1). Hese22 genes of the FGF family encode proteins that share about 25 to 55 percent sequence similarity within the core region (120-130 aa) . Among the 22 members of the FGF family, 4 of them (Fibroblast growth factor -11, -12, -13, -14) although show high sequence homology with prototypic FGFs, however, are unable to activate the FGFRs and are therefore not employed as FGFs. Instead, they have been entitled as Fibroblast homologous factors-FHFs. Whereas FGF-19 (human) is orthologous to FGF-15 (mouse) .
|Fibroblast growth factor||Gene||Location||Sequence
|Subcellular localization||Biological processes||Diseases||Other names|
|Fibroblast growth factor 1||FGF1||5q31||155||Secreted, Cytoplasm, Nucleus||Angiogenesis, innate immune response, MAPK cascade, etc.||Familial glomangiom, blount's disease||Acidic fibroblast growth factor; aFGF, Endothelial cell growth factor; ECFG, Heparin-binding growth factor; HBGF-1.|
|Fibroblast growth factor 2||FGF2||4q26-27||288||Secreted, Nucleus||MAPK cascade, regulation of angiogenesis, wound healing, etc.||Rheumatoid arthritis, Eye neovascular diseases, Neurodegenerative diseases, etc.||Basic fibroblast growth factor; bFGF, Heparin-binding growth factor 2; HBGF-2.|
|Fibroblast growth factor 3||FGF3||11q13||239||Secreted||Axon guidance, cell signaling, organ induction, etc.||Deafness withlabyrinthine aplasia, microtia, and microdontia (LAMM)||Heparin-binding growth factor 3; HBGF-3, Proto-oncogene Int-2|
|Fibroblast growth factor 4||FGF4||11q13.3||206||Secreted||Cell signaling, chondroblastdifferentiation, etc.||Teratocarcinoma, embryonal cancer||Heparinsecretory -transforming protein 1; HSTF-1, Heparin-binding growth factor 4; HBGF-4,
Transforming protein KS3
|Fibroblast growth factor 5||FGF5||4q21||268||Secreted||Positive regulation of cell proliferation, Ras protein signal transduction, etc.||Trichomegaly||Heparin-binding growth factor 5; HBGF-5, Smag-82|
|Fibroblast growth factor 6||FGF6||12p13||208||Secreted; extracellularspace||Cartilage condensation, signal transduction, etc.||Apert syndrome, breast cancer||Heparinsecretory-transforming protein 2; HSTF-2, Heparin-binding growth factor 6; HBGF-6|
|Fibroblast growth factor 7||FGF7||15q15-21.1||194||Secreted||EGFR signaling pathway,
|Bazex syndrome,familial progressive hyperpigmentation||Heparin-binding growth factor 7; HBGF-7, Keratinocyte growth factor|
|Fibroblast growth factor 8||FGF8||10q24||233||Secreted||Structural morphogenesis, aortamorphogenesis, apoptoticprocess, etc.||Hypogonadotropichypogonadism 6||Androgen-induced growth factor; AIGF, Heparin-binding growth factor 8; HBGF-8|
|Fibroblast growth factor 9||FGF9||13q11-q12||208||Secreted||Angiogenesis, axon guidance, cell-cell signaling, etc.||Multiple synostoses syndrome 3||Glia-activating factor - GAF,
Heparin-binding growth factor 9; HBGF-9
|Fibroblast growth factor 10||FGF10||5p12-p13||208||Secreted||Actincytoskeletonreorganization, activation of MAPK activity, thymus development, etc.||Lacrimo-auriculo-dento-digital syndrome, Aplasia of lacrimal
andsalivary glands (ALSG)
|Keratinocyte growth factor 2|
|Fibroblast growth factor 11||FGF11||17p13.1||225||Extracellularregion||Cell-cell signaling,
nervous system development, signal transduction, etc.
|-||Fibroblast growth factor homologous factor 3; FHF-3|
|Fibroblast growth factor 12||FGF12||3q28||243||Nucleus||nervous system development, neuromuscularprocess, etc.||Brugada syndrome||Fibroblast growth factor homologous factor 1; FHF-1,
|Fibroblast growth factor 13||FGF13||Xq26||245||Cell projection, Nucleus, Cytoplasm||Cerebral cortex cell migration,
establishment of neuroblastpolarity, etc.
|Wildervanck syndrome, borjeson-forssman-lehmann syndrome||Fibroblast growth factor homologous factor 2; FHF-2|
|Fibroblast growth factor 14||FGF14||13q34||247||Nucleus||Regulation of postsynaptic membrane potential and synapticplasticity, etc.||Spinocerebellarataxia 27||Fibroblast growth factor homologous factor 4; FHF-4|
|Fibroblast growth factor 16||FGF16||Xq16||207||Secreted||Metabolic process,
neurotrophin TRK receptor signaling pathway, etc.
|Metacarpal 4-5 fusion (MF4)||-|
|Fibroblast growth factor 17||FGF17||8p21||216||Secreted||fGFR signaling pathway, innate immune response, IR signaling pathway, etc.||Hypogonadotropichypogonadism 20 with or withoutanosmia (HH20)||-|
|Fibroblast growth factor 18||FGF18||5q34||207||Secreted||Angiogenesis, axon guidance, cell-cell signaling, etc.||Congenitaldiaphragmatichernia||zFGF5|
|Fibroblast growth factor 19||FGF19||11q13.1||216||Secreted||Positive regulation of ERK1, ERK2, JNK cascade and glucose import, etc.||Primary Biliary Cirrhosis||-|
|Fibroblast growth factor 20||FGF20||8p21.3-p22||211||Secreted||Fc-epsilon and FGF receptor signaling pathway, etc.||Renal hypodysplasia/aplasia 2 (RHDA2)||-|
|Fibroblast growth factor 21||FGF21||19q13.1-qter||209||Secreted||Positive regulation of cell proliferation and ERK1/2 cascade, etc.||Renal hypodysplasia/aplasia 1 and 2, Parkinson’s disease||-|
|Fibroblast growth factor 22||FGF22||19p13.3||170||Secreted||Ras protein and small GTPase mediated signal transduction, etc.||Metabolic diseases||-|
|Fibroblast growth factor 23||FGF23||12p13.3||251||Secreted||Response to Mg ion and sodium phosphate, Vit D catabolic process, etc.||Hypophosphatemic rickets autosomal dominant (ADHR), Tumoral calcinosis hyperphosphatemic familial (HFTC)||Phosphatonin, Tumor-derived hypophosphatemia-inducing factor|
Table 1: Members of Fibroblast Growth Factor Family (Homo sapiens). The information mentioned above is to the widely expressed fibroblast growth factors, their genes, chromosomal locations along with their sequence lengths, cellular localization. FGFs are concerned with several biological activities and diseases .
The members of the fibroblast growth factor family are involved in diverse biological activities such as wound healing, MAPK cascade, angiogenesis, cell differentiation, cell growth and proliferation, axon guidance, neuron development, etc. FGFs are localized within the nucleus and cytoplasm (cytosol) whereas some of them function in the extracellular space. Other members, for instance, bFGF, get accumulated in the extracellular matrix and are activated by other factors [6-9]. The FGF ligands interact with their specific receptors, i.e. fibroblast growth factor receptors (FGFRs) leading to the activation of the intracellular signaling cascade . The FGFRs are tyrosine kinase receptors, encoded by four genes i.e. fgfr-1, fgfr-2, fgfr-3 and fgfr-4 . These receptors, upon interaction with FGFs, form complexes with their ligands and Heparin sulfate proteoglycans (HSPGs), undergo dimerization to initiate pathways that ultimately promotes the stimulation physiological and developmental processes. Genetic modifications within the FGF family or irregularities in the processes carried out by FGFs provoke several disorders of nervous system, renal system, defects in embryonic development, tumor proliferation and cancer metastasis (Table 1). FGFs have been related to several types of tumors and cancers in association with vascular endothelial growth factor (VEGF) where these growth factors operate to carry out angiogenesis [12-14]. Some of the FGFs are secreted into the extracellular environment while others function intracellularly. All fibroblast growth factors were known to function through paracrine signaling, but advancements in the recent years lead to the affirmation of FGF- 19, 21 and -23 as endocrine signaling molecules [15-18].
This article reviews data about the fibroblast growth factors, their receptors, and signaling pathways, structure and their biological roles, participation in cancer as well therapeutic and pharmacological implications of FGFs. Several studies have been conducted in the past to elucidate the various features of the FGF family. Using X-ray crystallography, NMR and other peculiar techniques, characteristic like 3D structure, domain structure, sequences, cell surface receptor complexes, expression, pathology, etc. have been exquisitely outlined in the literature.
Fibroblast growth factor-FGF family
The fibroblast growth factor family consists of 22 genes that encode particular proteins, FGFs. The fibroblast growth factor family is composed of related molecules ranging from 17 kDa to 34 kDa.The first FGFs to be discovered were aFGF (FGF-1) and the bFGF (FGF-2) from the brain and pituitary extracts of the bovine in the 1970s. In the upcoming years, various other FGFs were identified. Genes of FGF-3, FGF-4, FGF-5 and FGF-6 were isolated as oncogenes [19-21]. FGF-7 is also known as Keratinocytes growth factor and FGF-8 as a growth factor from the carcinoma cells (androgen-induced). FGF-9 was described to be associated with the nervous system and was isolated from glioma cells . Fibroblast growth factors 1 to 9 share a 30-70 percent sequence homology, though these FGFs are of different sizes ranging from 150 to 250 aa . Almost all the members of the FGF family experience ca. 120 similar amino acids i.e. about 16% to 65% sequence similarity .
The fibroblast growth factor family embodies only 18 FGFR ligands i.e. FGF1-FGF10, FGF16-FGF23. FGF11-FGF14, although share high structural as well as sequence similarity with the other FGF family members but they lack the capacity to activate the FGF receptors and are, thus, more correctly designated as FHFs, i.e. fibroblast homologous factors. Distinct amino acid residues that reside within the receptor binding site of FHFs are responsible for their inability to activate FGFRs. Assembly of FHFs excludes many amino acid residues that are critical for the binding of FHFs to the receptors .
On account of phylogeny and sequence similarity, members of the FGF family have been categorized into unique subfamilies account of phylogeny and sequence similarity. This classification includes FGF-1, FGF-4, FGF-7, FGF-9, FGF-8, FGF-11 and FGF-19 subfamilies (Figure 1). Phylogenetic analysis of the FGF subfamily indicates evolutionary and transformative linkages among the members of the gene family. FGFs have also been analyzed by gene chromosomal location to evaluate the evolutionary background of the gene family (Figure 2). This classification results in six subfamilies i.e. FGF1/2/5, FGF7/10/22, FGF3/4/6/19/21/23, FGF9/16/20, FGF11/12/13/14 and FGF8/17/18 subfamilies (Figure 1). Based on closely linked genes sharing similar chromosomal localities members have been assigned to a particular subfamily. For instance, FGF-1, FGF-2, and FGF-5 show close linkage to the Annexin 6, Annexin 5, and Annexin 3 genes, respectively. Therefore, FGF-1, -2 and -5 belong to the same subfamily.
Figure 2: Classification of the FGF superfamily into particular subfamilies based on chromosomal gene analysis (Itoh, Ornitz 2004). The ANXA gene is linked FGF-1, FGF-2, and FGF-5 genes. FGF-7, FGF-10, and FGF-22 are closely related to HCN gene. NPM gene has close linkage with FGF-8, FGF-17, and FGF-18 genes. A single subfamily contains FGF-4, FGF-3, FGF-6, FGF-19, FGF-21 and FGF-23 genes due to their linkage with CCND, PPFIA, and KCNA genes. FGF-9, FGF-16, and FGF-20 are linked to ZDHHC and MTMR gene whereas the FGF homologous factors (FGF11-14) are closely related to CLDN gene.
An FGF gene is typically composed of three exons, where exon 1 starts with a Met residue. However, there are some exceptions; for instance, FGF-2 and FGF-3 have particular sequences transcribed at their 5’ end [26-27]. In some FGFs, sub-exons are formed when exon 1 passes through the splicing process. Genes of the FGF family are dispersed or clustered (in some cases) throughout the genome. FGF-3, -4 and -19 genes are present on the 11q13 chromosome, 12p13 chromosome contains FGF-6 and -23 genes whereas 8p21-p22 chromosome profiles FGF-17 and -20 genes chromosome.
The domain structure of FGFs is composed of a core region of about 120 aa -140 aa, containing 28 conserved residues as well as six identical amino acid residues . Among the 28 conserved residues, 10 of them are involved in interactions with the fibroblast growth factor receptors . The homologous core region in most of the FGF members constitutes a cylindrical barrel formed by the precise folding of 12 antiparallel beta strands. Variable amino- and carboxy- terminals that border the core region of FGFs . Exceptions exist in the structure of FGF-1 and FGF-2. These two fibroblast growth factors own a triangular array (allocated within the beta-trefoil structure) formed by a peculiar arrangement of four beta strands . In FGF-2, among the 12 beta strands, two of them i.e. β10 and β11 possess essential aa residues that are involved in the formation of the primary binding site for heparin. This site is different from the site that interacts and binds with FGFRs .
155 aa protein (17-18 kDa) forms FGF-1, which is a nonglycosylated polypeptide that does not possess a distinct signal peptide and is in fact, secreted in the shape of a dimer linked by a disulfide bond and by an ATP-dependent pathway that features synaptotagmin-1 rather than the classical pathway . The domain structure of FGF- 1 characterizes an NLS-nuclear localization sequence that depicts the involvement of FGF-1 in DNA synthesis. The 18kDa non-glycosylated protein, FGF-2, is secreted as a monomer and forms four isoforms (22 kDa, 22.5 kDa, 24 kDa, and 34 kDa) based on the presence of different start codons. This growth factor is thought to perform its activities, both intracellularly and extracellularly. Apart from similar domains that FGF-3 shares with other members of the FGF family, it has an NLS motif located at the C-terminal . FGF-4 has two heparin binding sites within its 176 glycoprotein domain structure. FGF-5 is a precursor polypeptide that contains a signal peptide and a mature peptide, 17 aa and 251 aa, respectively. Its unique feature is that it has both types of glycosylation’s, i.e. N- and O- linked. FGF-6 could be secreted in three precursor isoforms (208, 198 and 175 amino acids) because it contains three different AUG (methionine) start codons. The keratinocyte growth factor, FGF-7, is synthesized as a glycosylated precursor protein that later matures to form the 163 amino acid activated form. The activated form of FGF-7 activity is thought to be hindered by heparin molecules . Three regular exons encode the members of the FGF family. However, in the case of FGF-8, exon one has been split up into four small exons followed by the typical exon 2 and 3. FGF-9 do not own a signal peptide but is secreted adequately, unlike FGF-1 and FGF-2. Known as the keratinocyte growth factor-2, FGF-10 contains a serine-rich motif located at the amino terminal and retains an oddly long signal peptide .
FGF-11, also known as FHF-3 (FGF homologous factor-3), maintains an NLS whereas its domain structure has no signal peptide. FGF-12 (FHF-1) possess two NLS sequences (designated as bipartite NLS) near the amino terminal as well as a typical NLS. FGF-13 (FHF-2) features an amino-terminal alternate splicing. FGF-14 has a secondary signal motif along with a bipartite NLS. FHF-4 lacks the typical signal peptide. FGF-16 and FGF-20 do not have the typical signal sequence, like FGF-9, and are, therefore, secreted like that of FGF-9. Like FGF-8, FGF-17s exon one is also divided into mini exons, leading to several amino terminal isoforms and the other exons i.e. two and three are the same as others. FGF-18 is a secreted glycosylated polypeptide that interacts with heparin molecules whereas FGF-19, FGF-21 and FGF- 23 lack the heparin binding site within their domain structures  (Figure 3).
Figure 3: Schematic representation of the domain structure of FGF family . Based on their secretion/action mechanism, the family members have been classified. N; amino terminus, SP; signal peptide/propeptide, NLS; nuclear localization signal, NLS*; nuclear localization signal at C-terminus (FGF-3), HBS; heparin binding site, SP*; uncleaved bipartite signal sequence (secreted), C; carboxy terminus, serine-rich motif (FGF- 10), Bipartite NLS (FGF-12/and or FGF-14).
Fibroblast growth factor receptors
As a result of either of the two possible mechanisms, several isoforms of the FGF receptors are expressed in humans. A) Expression of various FGF receptor genes or B) expression of particular splice variants that result from the alternative splicing of the same FGF receptor gene. Four genes (fgfr1, fgfr2, fgfr3 and fgfr4) encode these receptors. Seven isoforms of FGF receptors exist due to alternative splicing that occurs within the mRNA of fgfr1, fgfr2, and fgfr3 [38,39]. Isoforms include FGFR1b, 1c, FGFR2b, 2c, FGFR3b, 3c, and FGFR4. In some of them, splicing results in the removal of the Ig-I domain and acid box whereas Ig-III alternative splicing results in the formation of type b and c isoforms. Alternative splicing in Ig-III (carboxyl-terminal half), retains any one of the exons that lie within the domain region. Isoform IIIb (Ig-IIIb) and isoform IIIB results when the splice variant retains exon 8 or exon 9, respectively (Figure 4). Particular tissue types i.e. epithelial clans express isoform IIIb whereas mesenchymal clans express the isoform IIIc. The various isoforms of the FGF receptors display peculiar specificity and selectivity for different FGF ligands as well as the signal transduction pathway they activate, depending on the type of tissue and the targeted biological activity. The FGF members show increased affinity for particular isoforms. FGF-3, -7, -10, and -22 interacts with isoforms IIIb. Acidic FGF binds with both the isoforms, whereas the other 13 members of the FGF family bind to isoform IIIc . The gene of FGFR4 is exclusive in a sense since no isoforms for this gene exist.
Figure 4: Generalized structure of FGF receptor, displaying ectodomain and an intracellular domain [39,43]. N; amino terminal, three Ig-Like domains, acidic box, CHD; cell adhesion molecule homology domain, Heparin-binding site within Ig-II domain, TM; transmembrane domain, Juxtamembrane domain, NB; nuclear binding domain, KI; kinase insert, found between TKI and TKII i.e. tyrosine kinase subdomains, PLC site (FGFR1)-PLC gamma interacts with this particular site of FGFR1 within the cytoplasmic space, C; carboxy terminal.
Structure and signaling
The general arrangement of an FGF receptor features an extracellular domain, a transmembrane domain, and a tyrosine kinase cytoplasmic domain. The specific portions of the extracellular domain are a signal peptide followed by three Immunoglobulin-like (Ig-like) domains, designated as Ig-I, Ig-II, and Ig-III. An acid box (serine-rich acidic sequence) is present between Ig-I and Ig-II domains, within the linker region (Figure 4). Ig-I and the acid box might participate in autoinhibition of the receptor itself . Ig-II and Ig-III domains are important for determining ligand specificity and its binding. A heparin molecule that serves as a co-factor assists the functioning of the receptor and increases the efficacy of the receptor-ligand complex. Ig-II domain (166-177 amino acids) contains the receptor interaction site. Alternative splicing within the Ig-III area determines the isoform of FGFR. A juxtamembrane region is present downward the transmembrane portion of the receptor which then leads to the tyrosine kinase-TK domain. A kinase insert of around 14 amino acids divides the TK region into two functional kinases i.e. kinase 1 and kinase 2 or TKI-I and TKI-II. The carboxy-terminal of FGFR1 contains a PLC γ interaction site that binds with PLC γ within the cytoplasmic region. The CAM homology domain-CHD is involved in the formation of an endosome and nuclear transport of the receptor, FGFR1 .
When the FGF ligand binds to the FGF receptor through its secondary receptor binding site, the activated receptor undergoes dimerization. As the ligand approaches its receptor, it interacts with the Ig-II and Ig-III domains of the receptor and forms a complex. The complex is, indeed, a ternary complex since the heparin molecules are also involved in the formation of the compound. A fully operating complex is composed of FGF, FGFR, and Heparin molecules in the ratio of 2:2:2 to form a symmetrically positioned dimer. After the binding of the FGF ligand and the co-factor (heparin molecule), the receptor is activated i.e. dimerized, and the tyrosine kinase domains are now trans-phosphorylated mainly within the A-loop region. Phosphorylation of the cytoplasmic domain region is then extended to the carboxy terminal region, juxtamembrane region and kinase insert region. The PLC gamma site is also phosphorylated, which in turns activates the effector molecules within the cytoplasmic region. The most important signaling cascades that are triggered by the activation of FGFR are the RAS/MAPK pathway, PLC γ pathway, and PI3K/ Akt pathway. Heparin molecules or heparin sulfate proteoglycans participate in the formation and arrangement of the FGFR dimer. It functions to stabilize the interactions within the protein structures. In this case, it works to secure the attachment of FGF with the FGF receptor in a 1:1 ratio.
Considering the vast range of activities that FGFs perform within the extracellular environment, many efforts have been made to investigate their structure as well as their particular role in various malignancies and diseases. Due to the rapid evolvement of many cancer types, FGFs have provoked concern as the frontline players of cancer development due to their well-studied roles in directing cell proliferation, angiogenesis, and cell migration. Hence, the modern day research is more focused on finding out the likely job of FGFs and FGFRs in the advancement of individual tumors. In the upcoming section, the role of FGFs and FGFRs in various biological activities, tumor development, and cancer metastases will be discussed. Also, the inhibitors of FGFs/FGFRs used as therapeutic drugs for clinical trials will be reviewed (Figures 4 and 5).
Figure 5: A generalized representation of signaling pathways, mainly activated after the formation of FGF-FGFR-HSPG ternary complex. Phosphorylation of docking protein FRS2 provides distant sites for the activation of secondary proteins within the cytoplasmic region. FRS2 triggers RAS/MAPK and PI3K/Akt pathways, whereas PLC gamma is activated by directly interacting with the PLC γ site located at the carboxy terminal of FGFR. PLC gamma pathway upon activation stimulates several intracellular proteins. Among them, activation of PKC ultimately stimulates the MAPK cascade by phosphorylating RAF (by RAS). As a result of these signaling cascades, various biological processes are brought about, such as determining the polarity of the cell, differentiation, growth, etc.
FGFs and FGFRs: Roles in biological processes
FGFs and FGFRs function to promote cell proliferation, angiogenesis, cell survival, and cell migration particularly at inflammatory, tumor and other hypoxic sites surrounding the primary tumor region as well as within the normal extracellular environment to carry out normal physiological activities. The signal transduction pathways activated by FGFs are well-characterized and follow specific orders from the guiding proteins within the cellular environment. Eventually, the outcome observed is standardized according to the needs of the surrounding cells and tissues. FGFs carry out cell proliferation in epithelial cells, adipocytes, and endothelial cells . FGF-2 has been reported to raise the cell proliferation rate in MC3T3E1 osteoblast-like cells. When compared with other factors like TGF-β, PDGF, PGE2, etc., the pace with which FGF-2 increased the cell proliferation was recorded to be the highest . FGF1 and FGF-2 induce cell proliferation in HT-29 cell lines and neuroepithelial cells, respectively [45,46]. FGF-7 has been linked with the proliferation of epithelial cells . FGF-10 and FGF-18 have been associated with the cellular proliferation within prostate cancerous cells, osteoblasts, chondrocytes, etc. [48-50].
Members of the FGF family are actively involved in promoting the cellular movement to perform several activities. FGFs function to form well-characterized mesoderm layer by assisting the migration of cells . FGF-2 is involved in the migration of endothelial cells whereas both FGF-1 and -2 induce migratory properties in cochlear ganglion cells [52,53]. FGF-7 shows increased migratory properties in HPDE cells as well as in keratinocytes [54,55]. Cardiac cells (neural crest cells) show movement in response to FGF-8 signaling . Angiogenesis and cell differentiation are other activities that FGFs administer along with FGFRs in a directed and well-coordinated manner. FGFs regulate the cell differentiation mechanism of hESCs . FGF-2 promotes the chondrogenic ability of hMSCs , whereas FGF-7 and FGF-20 are responsible for the differentiation that occurs in keratinocytes and the conversion of stem cell to dopamine-producing neurons within monkeys, respectively. FGFs have been reported to be responsible for making angiogenesis liable within the standard as well as many cancerous settings. FGF1 and FGF2 are concerned with the occurrence of angiogenesis via endothelial cells . FGF-1 is a known angiogenic factor that triggers angiogenesis within the chorioallantoic membrane- CAM of chickens whereas FGF-9 has been described to stimulate angiogenesis during bone repair [60-62].
The functioning of FGFs in the process of wound healing is an intriguing phenomenon and marks another biological activity that is carried out in the presence of these GFs . The conduct of FGFs, particularly that of FGF-1 and -2, is well-defined in angiogenesis. Angiogenesis leads to the successful accomplishment of the wound healing process. Wound healing requires four phases (inflammation, contraction, repair and regeneration) to reach an outcome [64,65]. Evidently, FGFs have been proven to take part in three out of four phases of wound repairing . These GFs are found in the ECM as well as in the fibroblasts and endothelial cells . Usually, FGFs are thought to be expressed at a particular site as it encounters a wound . Inflammation, the first phase of wound healing, features various members of the FGF family i.e. FGF-1, FGF-4, and FGF-2 [69-71]. These FGFs attract other immune cells to the site of inflammation, control the proliferation of platelets since they have significant activity at inflammation sites . FGFs regulate the division of megakaryocyte progenitor cells at the point of inflammation. Endothelial cells and fibroblasts are present in the second phase of wound healing. These cells express certain FGFs that display their activity in the cellular proliferation of these cells . FGF-2 stimulates the migration of endothelial cells by the activation of uPA (urokinase-type plasminogen activator) . uPA when interacts with its receptor on the cell surface, in turn, converts plasminogen to plasmin that cleaves fibrin, causing fibrinolysis and promoting the movement of endothelial cells . ΑVβ3 cell-surface adhesion molecule characterizes another mechanism adopted by FGF-2 to facilitate the movement of endothelial cells. FGF- 7 plays a role in the final phase, regeneration, of wound healing [76,77]. FGFs induce the limb buds to evolve and grow gradually [78,79].
FGF and FGFRs: Roles in cancer
Various cancers express FGFs-FGFRs at an increased level. The signaling scheme of these growth factors reinforces the survival, growth, and dissemination of tumors. In cancer state, FGFs facilitates the tumors to propagate to secondary locations either by promoting angiogenesis or by guiding other angiogenic factors to bring about their activity. As a result of FGF-FGFR interactions, various cellular elements like transcription factors and secondary proteins are triggered. An orderly working of all these elements is crucial at every step of the cascade and loss of check at any point may lead to uncontrolled cell division and neoplasia [80,81]. Tumor cell proliferation marks overexpression of FGFs. These GFs may probably be expressed either by tumor cells or by the stromal cells found in the surrounding environment, in response to a signal received from tumor cells. They operate in a paracrine  or an autocrine manner [83,84], thereby targeting tumor or the stromal cells. Another possible undercover mechanism behind FGF participation in cancer is their release from the extracellular matrix – ECM . ECM, upon its degradation by MMPs, releases FGFs that are stored or trapped within by MMPs. Otherwise, FGFs may associate with a carrier protein that delivers these FGFs to their respective receptors and in turn activate them .
FGFs when overexpressed in the tumor microenvironment, invasive and metastatic properties are gained by the cancer cells. However, the expression of FGF receptors is more discriminatory when it comes to the type of tumor . FGFR1 signaling outlines prostate cancer progression. It’s possible due to the overexpression of FGFR1 in basal cells, prostate epithelial cells and prostate progenitor cells that are embodied by the basal prostate gland-benign . The ligands of FGFR1 i.e. FGF-1, 2, 8b and 17, also show increased expression in prostate cancer . Studies concerned with the role of FGFR1 in the progression of prostate cancer have reported that hyperplasia or neoplasia within the prostate epithelium is caused by a continuously activated form of FGFR1 . Another study revealed the possible cause of transition of non-malignant prostate cancer cells to the malignant phenotype. The shift of FGFR2 splice forms, IIIb to IIIc is concerned with the underlying mechanism behind the proliferation of prostate epithelial cells. As mentioned earlier, the expression of IIIb and IIIc isoforms are characterized by epithelial and mesenchymal cells, respectively. Furthermore, FGF-2, IIIc ligand, was also overexpressed indicating its role along with that of IIIc isoform in the epithelial cell division. Hence, the conversion of non-invasive epithelial cells to the malignant phenotype  is due to the switch that ensures the FGFR2 signaling through the IIIc isoform (expressed by mesenchymal cells and hence has the potency to invade surrounding tissues) rather than the IIIb isoform. FGFR2-IIIb isoform has also been described to possess repressive tumor properties. Therefore, the fgfr2- IIIb gene might be viewed as a tumor suppressor gene . However, further research is required to enlighten the mechanism that underlies the functioning of FGFR2-IIIb isoform .
Fibroblast growth factors are related to mammary gland carcinogenesis. Studies have confirmed that mammary oncogene families sometimes operate in cooperation with each other for the successful tumorigenesis of the mammary gland. Wnt1 was the first oncogene to be identified that was activated by MMTV . Shortly after its discovery, fgf3 oncogene was located at a separate locus. Subsequent selection of oncogenes for induction of mammary tumor development within the MMTV infected mice, correlated wnt1 and fgf3 genes .The link between FGFs and breast cancer aroused the probability to look for the particularities of the oncogenes mentioned above. During the RNA analysis of fgf3 and fgf4 oncogenes, their particular role in the mammary tumor DNA amplification was not establishment on an authentic ground. However, the CCND1 oncogene that lies close to the fgf3/4 genes on chromosome 11q was later found to be the active oncogene within the region. Indeed, fgf3/4 genes were being transcribed as mere “riders” of the amplicon containing the oncogene concerned with the disease [96,97]. Moreover, roles of FGF- 1, -2, and -8 have also been described in assorted types of breast cancers [98-100]. FGF receptors, on the other hand, have been associated with breast carcinogenesis. For instance, FGFR1, FGFR4 have been detected to be overexpressed in some types of BCs, studies report [101,102]. FGFs serve as special players of certain carcinogenesis process due to their cell proliferating, anti-apoptotic and angiogenic properties. FGFs and FGFRs participate in skin  and urothelial carcinogenesis . The MAPK pathway which is triggered by activation of FGFR1 has been related to the proliferation of tumor cells . This path indicates the role of Ras that is can be activated by two separate proteins, in the activation of MAPK. FRS2  and Shc-src homology 2 containing protein . Proliferating cells express both of these proteins. However, the mechanisms by which these proteins work is entirely different from one another, Point mutations, genetic alterations, alternative splicing that results in various splice variants and abnormal expression of FGFs and FGFRs have the potential to form cancer . Point mutations have the least connectivity with the disease advancement in humans. However, a point mutation in three out of four FGFRs i.e. FGFR1, 2 and 3, has been linked to several skeletal disorders. Genetic alterations that modify the arrangement of the genes leads to the synthesis of a different form of protein that does not function properly. For instance, the FGFR2 receptor in osteosarcoma cell line of rats is continuously activated, even in the absence of a ligand . Continuous activation of FGFR2 is due to a rearrangement that takes places within the carboxy-terminal region of the receptor. Other than this, overexpression of FGFR1 and FGFR2 has been reported in renal cell carcinoma . FGFR2 is overexpressed in breast cancer and gastric cancer [111,112]. Human myeloid cells, bladder carcinoma as well as urinary tract carcinomas overexpress FGFR3 [113-115]. Alternative splicing, on the other end, creates such variants that do not hold back their ability to help survive the tumor environment, facilitating its cells through various signal transduction pathways by devising desired results. Splice variants of FGFR2 are linked to the type of breast cancer. FGFRs variants have also been associated with ovarian cancer, prostate cancer, etc. [116,117].
Low-grade urothelial bladder carcinomas are reported to have FGFR3 mutations [118,119]. Glioblastoma is a type of brain tumor in adults. A subgroup of this tumor type has been described to be caused due to a fusion protein, mainly involving the tyrosine kinase domain of FGFR1 or 3 that has been fused with the TACC1 or 3 encoding regions [120,121]. FGFR3-TACC3 fusion proteins have been associated with bladder cancer, cervical cancer [122,123]. Other examples include overexpression of FGFR2-TACC3 in cholangiocarcinomas (CCAa). FGF receptor 2, on the other hand, has been illustrated to undergo mutation in cervical, endometrial and squamous cell lung cancer [124-126]. Missense mutations of FGFR2 can also occur in gastric and ovarian cancer [127,128]. Polymorphism of FGFR2 can be related to breast carcinoma, and the isoform FGFR2-IIIc polymorphism has been outlined in breast cancer (BC) caused by a BRCA2 mutation. An aggressive form of breast cancer has been correlated with FGFR3 overexpression  and another form of breast cancer malignancy has been associated with FGFR1. Squamous cell lung cancer and NSCLC is related to FGFR1 amplification or other less defined mechanisms [130,131]. A study featuring Caucasian males demonstrated FGFR4 allele Arg-388 mutation with an aggressive form of prostate carcinoma .
Fibroblast growth factors act as mitogenic agents thus compelling the cells to undergo division. They may also act as anti-apoptotic agents thereby supporting cell survival pathways. FGFs carry out their roles in cancer by acting as any of the agents mentioned above. FGF-1 and FGF- 2 are known potent mitogenic agents . The other FGFs such as FGF-3, -4 and -5 have also been related to maintaining the proliferative properties of individual cancer cells lines [134,135]. Cell survival by anti-apoptotic mechanism is, indeed, an alluring process that assists the tumor cells to escape the body defense attacks and in turn, show resistance to different therapeutic agents. FGF-2 has been depicted to govern various anti-apoptotic proteins, such as Bcl-2 and XIAP, within the cellular environment [136,137]. On the other hand, FGF-2 has been reported actually to make the cancer cells undergo apoptosis, such as MCF-7 breast cancer cell lines by the down-regulation of Bcl-2 structure . Lastly, FGFs have been resolutely linked with angiogenesis, discussed in the upcoming section.
FGFs and FGFRs: Roles in angiogenesis
Angiogenesis is the formation of new blood vessels into an organized vasculature system that operates to transport nutrients and supplements to the target cells and tissues that reside within a particular environment, either in the close surroundings or at other distant locations . Many pathological anomalies, as well as developmental mechanisms, have been characterized by angiogenesis that is carried out by several pro-angiogenic factors . Various stimulatory and inhibitory factors maintain an equilibrium which, when disturbed, can result in the generation of several disorganized vessels and therefore, owns the ability to agitate the non-malignant cancer setup and convert it into a malignant form of cancer . With the passage of time, the number of tumor cells within a local tumor microenvironment keeps increasing. These tumor cells tend to escape such surrounding due to the hypoxic conditions created by a large number of cells . Angiogenesis is, in fact, responsible for metastasizing various tumors since it facilitates the movement of tumor cells to other locations. Thus aiding in tumor progression and growth .
The generalized concept about angiogenesis involves the induction of endothelial cells by various growth factors like FGF  and VEGF , etc. Stimulation of ECs allows the endothelial cells (EC) to release various MMPs into the extracellular matrix . Numerous studies have been directed to investigate the role of fibroblast growth factors and their receptors in angiogenesis. In fact, these GFs are among the angiogenic factors that were first specified and are capable of triggering a pro-angiogenic environment that is suitable for carrying the process of angiogenesis. FGFs when to interact with FGFRs on the cell surface of EC, they directly promote tumor angiogenesis. FGFR1 and FGFR2 (in some cases) are only expressed by endothelial cells [147,148]. In the group of 22 FGF members, the role of FGF-1 (aFGF) and FGF-2 (bFGF) has been extensively demonstrated as angiogenesis promoting growth factors.
Members of the FGF family are involved in the favorable implementation of angiogenesis by actively maintaining the endothelial cell division, migration, ECM degradation processes and interactions between the cell receptors and effector molecules. When FGF-1, -2 and -4 activate FGF receptor 1 and 2, discrete cellular pathways are triggered that facilitate the maintenance of the proliferative environment of endothelial cells [149,150]. FGF-8b is also involved in carrying out the same kind of activity . When FGF-2 stimulate a proliferative response in ECs, PKC is upregulated . When down-regulated, PKC, in turn, diminishes the effect of FGF-2 and as a result, the mitogenic activity is lost. FGFs increase the expression of MMPs and uPA from endothelial cells. In the case of uPA, its receptor expression is, indeed, harmonized on the cell surface by FGF-1, -2 and -4 to increase the efficacy of ECM-degrading mechanism FGF-1, -2 and -4 . Gelatinase A (MMP-2) and gelatinase B (MMP-9) have the potency to carry out angiogenic activities . Their release from the endothelial cells is promoted by FGFs [155,156]. Angiogenesis requires the migration of ECs to form the new vessels. FGF-1,-2, -10 and 8b induce migratory features in endothelial cells. FGF-2 binds to its receptor and activates MAPK pathway thereby supporting the migration of endothelial cells [157-160]. Certain integrins, cell adhesion molecules, and cadherins mediate endothelial cells interaction with surrounding extracellular components. FGF-2 governs the expression of these molecules on the cell surface of endothelial cells, assisting in the cell distribution, cell-cell communication, and maturation [161,162]. Finally, endothelial cell organization and maturation to form the vessel lumen is simplified by the effect of FGF-2 and FGF-8b . This action of FGFs requires backing from several other elements like the expression of TIMPs, MMP-2, MMP-9, uPA, several integrin receptors, etc. Under the effect of FGF-2, signals from VEFG receptor 1 are also significant in the development of mature endothelial cells .
FGF-BP (FGF binding protein) is present in various tissues where FGF-2 or other members of FGF family are expressed. This protein competes with heparin sulfate molecules and interacts with FGF- 2 that is trapped in the extracellular matrix and facilitates its release . When bound to FGF-2, FGF-BP reduces the availability of bFGF to heparin sulfate molecules, stimulating the growth of prostate and adrenal cancer cells in an FGF-2 dependent manner [166,167]. Reduction in the levels of FGF-BP has been correlated with the inhibition of angiogenic activity within the xenograft models of squamous cell cancer, colon cancer as well as prostate cancer [168,169].
In certain inflammatory conditions, angiogenesis could be induced in response to an injury that may be caused by any external stress. Cells found in inflammatory conditions include mast cells, cytotoxic and helper T cells as well as phagocytic cells . Inflammation provokes the release of bFGF from these cells . Moreover, other traumatic conditions may result in the expression of FGF-2 from endothelial cells . Other factors that are responsible for the expedition of FGF-2 release from endothelial cells may c to the progression of angiogenic activities [173,174]. In addition to the data- mentioned above, excessive inflammation may also result in cell damage and hypoxic conditions. Hypoxia stimulates the synthesis of heparin sulfate proteoglycans, thus increasing the impartiality of endothelial cells to FGF-2 . On the other hand, damaged endothelial cells express increased levels of FGF-2, facilitating the synthesis of new vesselsangiogenesis [176,177].
A crosstalk mechanism exists within the tumor microenvironment where various factors coordinate with each other to make sure the survival of tumor cells. As the tumor progresses, the expression profile of tumors also evolves where particular pro- or anti-angiogenic factors may be expressed at one point but might be absent at another [178,179]. VEGF is known to regulate and manage the angiogenic process. Upon integration, FGF-2 and VEGF bring about complex mechanisms that are essential for carrying out angiogenic activities . However, the effect of these two GFs is evident at different stages of the process. Almost every step of angiogenesis expresses FGF whereas VEGF is usually observed at the initial phases of tumor development [181,182]. FGF-2 signaling triggers VEGF expression in endothelial cells. A decrease in the expression of VEGF reduces the levels of FGF-2 consequently. Blocking FGFR1 and FGFR2 reduces the levels of VEGF and neovascularization . A study reported an increase in the levels of VEGF and VEGFR1/2 along with the levels of an angiogenic factor Hif-1α, observed in epithelial cells of the prostate tumor, upon induction of FGFR1 [184,185]. FGFR1 functions to promote the paracrine signaling of VEGF on endothelial cells to execute angiogenesis. VEGF and VEGFR signaling pathway may be induced by FGFs, resulting in the indirect stimulation of angiogenesis. FGF-2 acts to enhance the expression of NRP-1, which serves as a co-factor in VEGF-VEGFR interactions. The expression of NRP-1, when observed in VSMCs, in turn, facilitates the cell migratory properties induced by VEGF , thus endorsing the angiogenic process. On the other hand, FGF-2 reinforces the secretion of HIF-1α that consequently releases VEGF . A reciprocal interaction exists among the VSMCs bearing FGFR1 and endothelial cells that retain PDGFR α and β. This peculiar communication is carried out by FGF-2, where it operates to make endothelial cells more responsive to PDGF-BB that in turn responses to VSMCs and promotes their reactivity towards FGF-2 by increasing FGFR1 expression. Angiogenesis carried out under the effect of FGF-2 is not entirely dependent on VEGF signaling. According to one report, even in the presence of high levels of VEGF, FGF-2 overexpression can induce angiogenesis . Apart from mediating the VEGF signaling, the FGFR1 is involved in reducing the levels of Angiopoietin 1 while augmenting the expression profile of Angiopoietin 2 . These are angiogenic factors that interact with their respective receptors (RTKs) on endothelial cells. Ang-1 is responsible for maintaining balanced and stabilized embryonic blood vasculature system . Paradoxically, Ang-2 is involved in the disruption of new blood vessels . The presence of Ang-2 and VEGF at the point of angiogenesis suggests the undermining effect of Ang-2 on endothelial cells makes these cells more responsive to VEGF-regulated angiogenesis.
Participation of fibroblast growth factors in commencing and implementing various angiogenic activities is quite evident. Numerous research studies conducted in the recent years have proved the role of FGFs in promoting tumor angiogenesis. However, most of the research administered was based either on animal models or in vitro studies. The link of tumor progression and tumor angiogenesis with FGFs in human cancer requires further affirmatory data. Respective therapeutic techniques have been investigated in various clinical trials to limit the operation of FGFs in the tumoral environment.
Therapeutic inhibition of FGFs-FGFRs
The association between cancer metastases and angiogenesis is genuinely acceptable. Efforts are being made to develop such kind of drugs that could ultimately limit the effect of FGFs on tumor angiogenesis and the crosstalk mechanism they undergo with various molecules within the tumor microenvironment . FGF-FGFR signaling, apart from directly participating in angiogenesis and tumor growth, is linked with resistance to various VEGF inhibitory therapies, confirming the actuality of cross talk system between FGF and VEGF . Upregulation of interactions among FGF and FGFR may result in resistance to an anti-VEGF therapy . In certain malignancies, FGFs have been reported to hinder the inhibitory action of therapies targeted against VEGF-mediated signaling activities. When studied in transgenic mice models of pancreatic tumor, Rip1-Tag2, blocking of VEGFR elevated the levels of FGF-2. Upon treatment of the same tumor with VEGFR inhibitor alone and later on with an FGF-trap, the result recorded was a decrease in vessel density and tumor progression .
Various types of therapeutic drugs have been manufactured and tested for their inhibitory actions against FGFs and VEGF since these two GFs show a highly integrated response mechanism that leads to tumor angiogenesis . Inhibitors developed against VEGF or FGF usually aims the growth factor itself, its receptor or any downstream signaling molecule angiogenic activities [197-199].
Bevacizumab, rhumAb VEGF, is a recombinant monoclonal antibody that binds to VEGF-A growth factor and hinders its interaction with its receptor thus down-regulating angiogenesis, investigated in various studies. However, FGFs’ show resistance to its mode of action [200,201]. A treatment study of bevacizumab along with 5-fluorouracil (5-FU), leucovorin, and irinotecan (FOLFIRI) was carried out on the patients of colon cancer to demonstrate the role of FGF-2 against bevacizumab. At various levels of disease progression, FGF-2 levels were assessed. The results displayed an increase in the levels of FGF- 2 just before cancer progression [202,203]. Another study concerned with renal cancer neoadjuvant therapy included bevacizumab along with other radiations. Here too, FGF-2 showed no response to this treatment, suggesting resistance to bevacizumab [204,205]. An antibody directed against VEGF receptor 2 KDR/Flk-1 obstructs the binding of VEGF with VEGFR2, thus attenuating the signaling pathways directed by VEGF-VEGFR2 interaction . SU6668 is an inhibitor that aims to interrupt the kinase activity of FGFR, VEGF, and PDGFR. Interferon is correlated with inhibition of angiogenesis . Interferon α reduces angiogenic activity that is being maintained by increased levels of FGF-2. It also decreases the expression of FGF-2 from tumor cells. Another inhibitor of FGF-2 induced angiogenesis is thalidomide, which is an immunomodulatory drug . Platelet factor 4 is a CXC chemokine that possesses anti-angiogenic properties. It interacts with FGF-2 and heparin sulfate simultaneously to form a ternary complex and inhibits angiogenesis by binding with FGF-2/HS at the cell surface. It also obstructs the dimerization of bFGF [209,210].
In the past years, advancements in pharmaceutical therapies against FGFs have been made to limit their effects on the cancerous environment. Though, tumor angiogenesis is mainly regulated by VEGF and passively by FGF. However, fibroblast growth factors resist the effects of anti-VEGF therapies, as mentioned earlier. Recently developed techniques against growth factors target FGF receptors to limit angiogenesis. Individual tyrosine kinase inhibitors are being developed, known as “small molecule TKIs” that may act against FGFs either specifically or as a part of the larger target group depending on their mode of action . The primary strategy applied here is to block the ATP binding site of the FGFR receptor. The intracellular tyrosine kinase domain of FGFR contains the ATP site. The “non-specific” TKIs class usually, targets VEGFRs as well as FGFRs since these two have almost identical kinase domain structure. However, nonspecific TKIs have a higher potency to select VEGFR as compared to FGFR [212,213].
Dovitinib (TK1258) is a tyrosine kinase inhibitor that works against several factors like VEGFR1, 2, 3; FGFR1; PDGFR-β; CSf- 1, etc. This compound possesses antitumor and anti-angiogenic properties when it targets receptors like FGFR, PDGFR or VEGFR, FGFR, and PDGFR, respectively. Dovitinib has been investigated in gastrointestinal stromal tumors, endometrial, breast, hepatocellular carcinomas, etc. [214-219]. Side effects recorded in different studies mainly included diarrhea, hypertension, abdominal pain, nausea, dehydration, etc. . E3810 (may or may not be labeled as lucitanib) acts as a dual inhibitor of FGFR1/2 and VEGFR1/2/3 that can be administered orally and is currently in phase II clinical trials. Side effects reported were hypertension, hyperthyroidism, etc. [221-223]. Nintedanib (BIBF1120) is another non-specific TKI that targets VEGFR, FGFR as well as PDGFR. Phase II clinical trials of nintedanib are under way for endometrial cancer, hepatocellular carcinoma, glioblastoma multiform and prostate cancer, etc. This inhibitor mainly causes gastrointestinal side effects . Used as a leading therapy for chronic myelogenous leukemia, Ponatinib (AP24534) is a BCR-ABL tyrosine kinase inhibitor. It also shows anti-angiogenic properties against FGFR1, VEGFR2, PDGFRα, etc. [225,226]. Apart from the above mentioned prominent non-selective TKIs other compounds, like brivanib (BMS582664) a dual FGFR/VEGFR inhibitor, ENMD- 2076, lenvatinib (E7080), orantinib (TSU-68), etc., though have shown anti-FGFR properties. However, their effects against VEGFR or other kinases are more relevant [227-230].
“Selective” TKIs are the other class of inhibitors that specifically target FGFRs. BGJ398 is a selective TKI that targets FGFRs1-3. This compound, either exclusively or in combination with other compounds, is being investigated in various phase II clinical trials of certain tumors [231,232]. The other two selective TKIs are pan (Greek meaning all) inhibitors i.e. they block all FGFRs indiscriminately. These inhibitors are AZD4547 and LY287445 [233,234]. The former is being tested in phase I and II clinical trials whereas the latter has been tested in breast cancer patients during a phase I clinical trial. TAS120, Debio1347, JNJ- 42756493, and ARQ087 are other specific tyrosine kinase inhibitors that have been developed to hinder the activity of FGFRs . Besides tyrosine kinase inhibitors, other forms of therapies have evolved in the recent years to hinder the activity of FGFRs. These types include monoclonal antibodies directed towards FGFRs [236,237] and FGFligand traps. The novel strategy for blocking FGF/FGFR interaction is the ligand trap. It has the potency to hinder the binding of FGF ligand with its respective receptor. MGFR1877S is a monoclonal antibody that targets FGFR3. FP-1039 is an FGF ligand trap that has been developed by combining the regions of human IgG and extracellular domain region of FGFR1-IIIc isoform .
The developmental steps of FGF/FGFR inhibitors have come across various challenges. When it comes to limiting angiogenic process within a cancerous setting, FGFs or FGFRs alone are not solely responsible for carrying out this particular process. FGF/FGFR targeted remedies need to be combined with other therapies to attain the desired result. Further evaluation of tumor microenvironment and various factors that reside within is required. The timing for the application of a certain therapy is another hurdle. The tumor environment is a dynamic environment that keeps on modifying its expression profile. Hence, any tumor would have unique FGF/FGFR expression levels at certain points, and these levels may decrease or increase as the tumor advances. On the other hand, in such a complex environment administration of a certain therapy usually, faces resistance from some other factor. Identification of such factors makes the developmental process even complicated and time-consuming. Furthermore, selection of patients for conducting a clinical trial, cost effectiveness of therapy, possible adverse outcomes, recurrence time, etc. are some other factors that need to be figured out before launching a treatment against the FGF/FGFR activity.
FGFs’ expression shows resistance to anti-cancer therapies in certain tumors. In the excess of ligands i.e. GFs, the response of cancer cells to tyrosine kinase inhibitors is impaired. FGF is expressed by stromal cells and resists the anti-cancer effects of imatinib in gastrointestinal stromal cancer. FGFs decrease the anti-cancer effects of imatinib in a mice model of cervical carcinogenesis. FGF-2, when administered on a cell line of human bladder cancer, shows resistance to cisplatin therapy . According to one study, FGF-1 and FGF-2 also resist the response of paclitaxel, doxorubicin, and 5-fluorouracil in metastatic tumors . FGFs and FGFRs resist individual therapies that target cancer cells. In a breast cancer study, FGFR1 overexpression has been correlated with the induction of resistance to 4-hydroxytamoxifen. Certain novel inhibitory techniques have been developed that lower the expression of EGFR along with that of FGFR3 and FGFR2 in the cell lines of non-small cell lung cancer-NSCLC . In a particular type of melanoma, the activation of MAPK pathway by FGFR3 results in the resistance to vemurafenib, an anti-cancer drug . A crosstalk mechanism that exists between FGFR3 and KIT gene induces drug resistance in gastrointestinal stromal cancer . FGFR3 hinders the effects of dexamethasone in multiple myeloma cells . FGFR4 has been linked with drug resistance in colorectal cancer . Selective mutations in FGFR2 can lead to resistance to dovitinib.
An enormous amount of data is available to validate the role of FGF and FGFR in drug resistance. Development of FGF/FGFR combined resistant drugs and exclusively designed clinical trials that implement a combined treatment of specific anti-cancer drugs would help achieve the standardized outcome in the future.
Several biological and developmental processes that take place during the lifespan are brought about by Fibroblast growth factors. These growth factors act as ligands and upon binding to their receptors- FGFRs and cooperating with co-factors, i.e., heparin sulfate molecules/ HSPG, trigger a signal transduction cascade that ultimately lead to cell proliferation, cell survival, angiogenesis and other mechanism carried out by this class of GFs. FGFs may act in an endocrine, paracrine or an intracrine manner depending upon their domain structure and secretion.
FGF/FGFRs play a distinct role in facilitating tumor progression and angiogenesis. With the assistance of other elements, particularly VEGF in the case of angiogenesis, FGFs can implement the angiogenic process. Since their discovery in 1970’s and revelation of their structure and mode of action in cancer, attempts have been made to restrict their activity. Clinical trials have evaluated several pharmaceutical remedies. Advanced schematic analysis of tumor microenvironment, for isolating determinants that coordinate with the surrounding components to form an alliance and operate as a compact unit to favorably actuate the mechanism of angiogenesis and tumor survival is required. Detailed studies on cancer types specified by FGFs and FGFRs would provide a lead in the future for the better development of medicinal therapeutics.